News - Pfizer, Pharmaceutical

Filter

Current filters:

PfizerPharmaceutical

Popular Filters

1 to 25 of 347 results

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

New indications approved in EU for Bristol-Myers/Pfizer Eliquis

30-07-2014

The European Commission has approved US pharma majors Bristol-Myers Squibb and Pfizer’s Eliquis (apixaban)…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Earnings at Pfizer tank but still just beat expectations

Earnings at Pfizer tank but still just beat expectations

29-07-2014

Taking the brunt of generic competition to former blockbuster drugs, US pharma giant Pfizer posted a…

FinancialPfizerPharmaceuticalUSA

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

Pfizer’s BeneFIX reduces bleeding rates in Ph III study

Pfizer’s BeneFIX reduces bleeding rates in Ph III study

16-07-2014

US pharma giant Pfizer today released positive results of a Phase III study comparing a prophylaxis regimen…

BenefixHaemophiliaHematologyHemophilia BPfizerPharmaceuticalResearchSevere hemophilia BUSA

UK Business Secretary to set out new takeover rules

UK Business Secretary to set out new takeover rules

13-07-2014

UK Business Secretary Vince Cable is shortly to announce new regulations to deal with foreign takeover…

LegalMergers & AcquisitionsPfizerPharmaceuticalUKVince Cable

Varenicline combined with nicotine patch improves smoking cessation rates

Varenicline combined with nicotine patch improves smoking cessation rates

09-07-2014

Combining the smoking cessation medication varenicline with nicotine replacement therapy was more effective…

ChantixNeurologicalNicotinePfizerPharmaceuticalResearchSmoking cessationUSAVarenicline

England’s community prescribing rises almost 60% but costs increase only 15% in 10 years

England’s community prescribing rises almost 60% but costs increase only 15% in 10 years

09-07-2014

The number of prescription items dispensed in the community in England has increased by 58.5% over 10…

atorvastatinHealthcareLipitorPfizerPharmaceuticalUK

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Pfizer inks multi-million $ cancer immunology deal with Cellectis

Pfizer inks multi-million $ cancer immunology deal with Cellectis

18-06-2014

France-based genome engineering specialist Cellectis saw its shares rocket nearly 50% to 9.26 euros,…

CellectisLicensingMergers & AcquisitionsOncologyPfizerPharmaceutical

MRC Technology sells its melanocortin receptors program to Pfizer

MRC Technology sells its melanocortin receptors program to Pfizer

18-06-2014

UK-based technology transfer organization MRC Technology has sold its melanocortin receptors (MCRs) program,…

LicensingMRC TechnologyPfizerPharmaceutical

Pfizer agrees to pay $325 million over Neurontin

Pfizer agrees to pay $325 million over Neurontin

03-06-2014

US pharma giant Pfizer has agreed a $325 million settlement over a trial regarding the marketing of Neurontin…

CNS DiseasesLegalNeurontinPfizerPharmaceuticalUSA

Morris Birnbaum joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research

Morris Birnbaum joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research

30-05-2014

US pharma giant Pfizer has announced that Morris Birnbaum has joined the company as Chief Scientific…

BoardroomPfizerPharmaceuticalUSA

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

28-05-2014

The record start to 2014’s pharma M&A has been a welcome boost to a deal market that had been in the…

CancerGlobalInterviewsMergers & AcquisitionsPfizerPharmaceuticalPharmaceutical industryPharmaceutical sciences

AstraZeneca safe (for now?) as Pfizer walks away from pursuit of the firm

26-05-2014

US pharma giant Pfizer, which has been involved in a controversial pursuit of UK-based AstraZeneca, has…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pfizer’s tofacitinib meets primary endpoints in Ph III psoriasis study

26-05-2014

US pharma giant Pfizer on Friday announced positive results from the Oral treatment Psoriasis Trial (OPT)…

Anti-Arthritics/RheumaticsDermatologicalsPfizerPharmaceuticalResearchtofacitinib

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

19-05-2014

After what must have been a hectic weekend of cross Atlantic activity, the board of Anglo-Swedish drug…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pfizer to submit NDA for breast cancer drug palbociclib later this year

18-05-2014

US pharma giant Pfizer says that it will submit a New Drug Application with the US Food and Drug Administration…

OncologypalbociclibPfizerPharmaceuticalRegulationUSA

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

13-05-2014

As the arguments continue over the benefits or otherwise of US pharma giant Pfizer’s £63 billion ($106…

AstraZenecaMergers & AcquisitionsPfizerPharmaceuticalPoliticsUK

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

1 to 25 of 347 results

Back to top